113
Registered trials
41
Recruiting
60
Completed trials
58
Sponsors
25
Countries
Phase III:
56
Phase II/III:
6
Phase II:
34
Phase I/II:
8
Phase III/IV:
1
Phase IV:
2
Phase I:
1
Phase I (Other):
2
Phase I (FiH):
3
Oversight events:
4 serious breaches
48 temporary halts
5 urgent safety measures
5 corrective measures
across 16 trials
View oversight register →
Indications tested
Non-small cell lung cancer
41
Non-small cell lung cancer metastatic
15
Non-small cell lung cancer stage IV
8
Non-small cell lung cancer recurrent
3
Non-small cell lung cancer stage IIIB
3
Non-small cell lung cancer stage III
3
Skin cancer
1
ALK gene rearrangement positive
1
HER2 mutant non-small cell lung cancer
1
Medullary thyroid cancer
1
Renal cell carcinoma
1
EGFR gene mutation
1
Sponsors using this IMP
AstraZeneca AB
16
F. Hoffmann-La Roche AG
7
Bristol-Myers Squibb Services Unlimited Company
6
Merck Sharp & Dohme LLC
6
Intergroupe Francophone De Cancerologie Thoracique
5
Regeneron Pharmaceuticals Inc.
5
AbbVie Deutschland GmbH & Co. KG
4
Revolution Medicines Inc.
4
Bristol Myers Squibb International Corporation
3
Daiichi Sankyo Inc.
3
Fondazione Ricerca Traslazionale
3
Boehringer Ingelheim Espana S.A.
2
All trials — page 2
113 totalShowing 25–48 of 113 trials